SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
154.40    1.60 (1.05%)
Bid:
154.40
Ask:
154.80
Spread: 0.40 (0.259%)
Market Cap: £883.65m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Q3 Trading Update

25 Oct 2018 07:00

RNS Number : 1088F
Elementis PLC
25 October 2018
 

Elementis plc

Q3 Trading Update

 Resilient overall performance, confident of continued progress in 2018

Elementis plc ("Elementis" or the "Group"), a global Specialty Chemicals Company, today issues its period end trading update for the three months ended 30 September 2018.

The Group has delivered resilient performance in the third quarter, and overall is on track and confident of making further financial and strategic progress in 2018.

Business Performance

· In Personal Care solid performance in the period was supported by growth in sales to direct customers of our unique, high margin hectorite based products and the successful delivery of SummitReheis synergies.

 

· In Coatings our transformation programme continues to gather pace as we optimise the product portfolio, implement efficiency measures and execute price increases. In Q3, performance in Europe and the Americas was similar to the first half but Asia has been impacted by weaker volumes and currency headwinds, primarily in China, as a result of an economic slowdown.

 

· Activity levels in Energy have improved driven by new business and early signs of recovery in deep water drilling. We continue to expect a sequential improvement in performance in the second half of the year.

 

· In Chromium, as previously communicated, production at Castle Hayne was temporarily suspended in September due to Hurricane Florence and subsequent flooding. Production has since restarted, and whilst we expect some mitigation from insurance, this outage will adversely impact Chromium full year operating performance. Otherwise, demand remains strong with supportive pricing momentum expected in 2019.

Mondo Minerals Acquisition

Completion of the Mondo Minerals acquisition on 23 October represents a material new growth opportunity for Elementis. In 2018 Mondo continues to trade in line with our expectations, and is experiencing good momentum going into 2019.

Strong cash generation

Elementis' strong free cash generation continued in Q3 and was enhanced by the disposal of our Jersey City site for $17m in August. Including the sale of the Surfactants business in February, this brings cumulative proceeds from asset disposals to over $60m in 2018.

Having completed the acquisition of Mondo Minerals, a material deleveraging profile is envisaged for the Group and this will be accelerated by the outcome of the triennial review of the UK pension scheme that concluded no cash top up payments are required from Elementis until at least 2021. This contrasts to the previous three years where total contributions were $32m.

 

Commenting on the performance, CEO, Paul Waterman said,

 

"Overall performance in the third quarter has been solid. We continue to implement our Reignite Growth strategy, focusing resources on higher margin growth opportunities, high grading our business portfolio and driving both cost and capital efficiency. In addition we are excited to begin the integration of Mondo Minerals at pace. "

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

Martin Robinson/David Allchurch, Tulchan Tel: 020 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTMIBLTMBATBAP
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.